FRI0311 TRANSVERSAL STUDY OF CARDIAC RHYTHM DISORDERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 746.1-746
Author(s):  
C. Rodríguez-López ◽  
E. Vicente ◽  
E. Tomero Muriel ◽  
J. P. López-Bote ◽  
L. Vega ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Ankylosing Spondylitis ◽  
General Population ◽  
Sample Size ◽  
Body Mass ◽  
Heart Rhythm ◽  
Small Sample ◽  
Hla B27 ◽  
Research Support ◽  
Heart Rhythm Disorders

Background:Ankylosing spondylitis (AS) has been associated with different comorbidities, particularly some of cardiac origin. Recently, some studies have been published that suggest that certain arrhythmias may be more frequent in AS than in the general population.Objectives:To estimate the prevalence of arrhythmias in patients diagnosed of AS in our environment and to compare it with that of the general population.Methods:Descriptive cross-sectional study in patients diagnosed with AS by New York criteria, seen in our Department from 1st January 2018 to 30th March 2019, with age ≥ 18 years. A baseline 12-lead ECG was performed unless patients already had an ECG or a 24-hour Holter in the previous year. Likewise, demographic and disease-related variables were collected, such as: sex, age, body mass index (BMI), HLA-B27, year of diagnosis, pattern of involvement, comorbidities, ESR and CRP, BASFI and BASDAI (scales of 0 to 100), questionnaire about physical exercise, tobacco habits and treatments received. Descriptive statistical analysis was performed by calculating means with their standard deviation (SD) and percentages with their confidence intervals (CI). Prevalence of arrhythmias obtained in AS was compared with studies that determined the prevalence in the general population (statistical tool: SPSS).Results:117 patients with AS (62.4% men), mean age 54.8 years (± SD: 15.7), disease progression of 14.7 ± 9.6 years were included. HLA B27 was positive in 75.4%. Mean values of ESR and CRP were 14.4 mm/h and 0.6 mg/dl, respectively, and the average of the BASFI and BASDAI scores were 26/100 and 30/100, respectively. The prevalence of heart rhythm disorders was 19.7% (95% CI 12.3-27.0), which was significantly associated with advanced age, arterial hypertension and body mass index (BMI). No association was found with other activity or functional disease parameters (CRP, BASDAI, BASFI). The rhythm disorders found were: 9.4% (95% CI: 4.0-14.8) of the patients presented supraventricular tachyarrhythmias; 7.7% (95% CI: 2.7-12.6) had atrioventricular blocks and 6.8% (95% CI: 2.2-11.5) intraventricular conduction disorders. Although no differences were found regarding the prevalence described in the general population, an associative trend was observed, although it did not reach statistical significance probably due to the small sample size recruited.Conclusion:There seems to be an increased tendency of heart rhythm disorders in patients with AS compared to the general population, which may have clinical and therapeutic implications. However, studies with larger sample size are needed to corroborate these results. In addition, there was a relationship between the presence of arrhythmias and certain pro-inflammatory situations (older age and BMI, although not CRP), which supports the hypothesis that some underlying inflammation status in these patients could partly justify an increased arrhythmogenesis.Disclosure of Interests:Carlos Rodríguez-López: None declared, Esther Vicente Speakers bureau: BMS, Roche., Eva Tomero Muriel: None declared, Juan Pedro López-Bote: None declared, Lorena Vega: None declared, Isidoro González-Álvaro Grant/research support from: Roche Laboratories, Consultant of: Lilly, Sanofi, Paid instructor for: Lilly, Speakers bureau: Abbvie, MSD, Roche, Lilly, Alicia Humbría: None declared, Jesús Jiménez Borreguero: None declared, Rosario Garcia de Vicuna Grant/research support from: BMS, Lilly, MSD, Novartis, Roche, Consultant of: Abbvie, Biogen, BMS, Celltrion, Gebro, Lilly, Mylan, Pfizer, Sandoz, Sanofi, Paid instructor for: Lilly, Speakers bureau: BMS, Lilly, Pfizer, Sandoz, Sanofi, Fernando Alfonso Manterola: None declared, Santos Castañeda: None declared

scholarly journals The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3245
Author(s):  
Emma C. Atakpa ◽  
Adam R. Brentnall ◽  
Susan Astley ◽  
Jack Cuzick ◽  
D. Gareth Evans ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Body Mass ◽  
Breast Density ◽  
Small Sample ◽  
Weight Loss Intervention ◽  
Short Term ◽  
Dense Area ◽  
Short Term Change ◽  
Term Change

We evaluated the association between short-term change in body mass index (BMI) and breast density during a 1 year weight-loss intervention (Manchester, UK). We included 65 premenopausal women (35–45 years, ≥7 kg adult weight gain, family history of breast cancer). BMI and breast density (semi-automated area-based, automated volume-based) were measured at baseline, 1 year, and 2 years after study entry (1 year post intervention). Cross-sectional (between-women) and short-term change (within-women) associations between BMI and breast density were measured using repeated-measures correlation coefficients and multivariable linear mixed models. BMI was positively correlated with dense volume between-women (r = 0.41, 95%CI: 0.17, 0.61), but less so within-women (r = 0.08, 95%CI: −0.16, 0.28). There was little association with dense area (between-women r = −0.12, 95%CI: −0.38, 0.16; within-women r = 0.01, 95%CI: −0.24, 0.25). BMI and breast fat were positively correlated (volume: between r = 0.77, 95%CI: 0.69, 0.84, within r = 0.58, 95%CI: 0.36, 0.75; area: between r = 0.74, 95%CI: 0.63, 0.82, within r = 0.45, 95%CI: 0.23, 0.63). Multivariable models reported similar associations. Exploratory analysis suggested associations between BMI gain from 20 years and density measures (standard deviation change per +5 kg/m2 BMI: dense area: +0.61 (95%CI: 0.12, 1.09); fat volume: −0.31 (95%CI: −0.62, 0.00)). Short-term BMI change is likely to be positively associated with breast fat, but we found little association with dense tissue, although power was limited by small sample size.

scholarly journals Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project

2021 ◽  
Vol 10 (3) ◽  
pp. 382
Author(s):  
Jesús A. Valero-Jaimes ◽  
Ruth López-González ◽  
María A. Martín-Martínez ◽  
Carmen García-Gómez ◽  
Fernando Sánchez-Alonso ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Body Mass ◽  
Rheumatic Diseases ◽  
Activity Index ◽  
Response To Therapy ◽  
Inflammatory Rheumatic Diseases ◽  
Psoriasis Area Severity Index ◽  
Chronic Inflammatory Rheumatic Diseases

Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m2) was >30 according to the WHO criteria. Scores used to evaluate disease activity were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS, and 721 PsA) were assessed. The mean ± SD BMI at the baseline visit were: 26.9 ± 4.8 in RA, 27.4 ± 4.4 in AS, and 28.2 ± 4.7 in PsA. A positive association between BMI and disease activity in patients with RA (β = 0.029; 95%CI (0.01–0.05); p = 0.007) and PsA (β = 0.036; 95%CI (0.015–0.058); p = 0.001) but not in those with AS (β = 0.001; 95%CI (−0.03–0.03); p = 0.926) was found. Disease activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can improve the outcome of patients with CIRD and, therefore, weight control should be included in the management strategy of these patients.

scholarly journals AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1717.2-1718
Author(s):  
C. T. Ritchlin ◽  
A. Ogdie ◽  
J. T. Giles ◽  
J. J. Gomez-Reino ◽  
P. Helliwell ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Janus Kinase ◽  
Inadequate Response ◽  
Tnf Inhibitor ◽  
Efficacy And Safety ◽  
Lipid Levels ◽  
Research Support ◽  
Link Type ◽  
Advanced Therapies

Background:Obesity is highly prevalent in PsA (~45%)1and is associated with a reduced response to TNF inhibitors.2Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.Objectives:This post hoc analysis assessed tofacitinib efficacy and safety in patients (pts) with PsA by baseline (BL) body mass index (BMI) category.Methods:Data were pooled from two placebo (PBO)-controlled, double-blind, Phase 3 studies in pts with active PsA and an inadequate response to ≥1 conventional synthetic DMARD (OPAL Broaden [12 months;NCT01877668]) or to ≥1 TNF inhibitor (OPAL Beyond [6 months;NCT01882439]).3,4This analysis included pts randomised to tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID or PBO, stratified by BL BMI: <25 kg/m2, ≥25–<30 kg/m2, ≥30–<35 kg/m2, or ≥35 kg/m2. Efficacy and safety were reported to Month (M)3. M3 efficacy outcomes included ACR20/50/70 and HAQ-DI responses, dactylitis and enthesitis resolution rates and changes from BL in HAQ-DI, Short Form-36 Version 2 (SF-36v2) Physical (PCS) and Mental Component Summary (MCS) scores, and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores. Safety outcomes included adverse events (AEs), such as cardiovascular (CV) events and changes in lipid levels and liver function tests (LFTs).Results:This analysis included 710 pts; 43.8% were obese (BMI ≥30). At BL, 161 (22.7%) pts had a BMI <25, 238 (33.5%) had a BMI ≥25–<30, 186 (26.2%) had a BMI ≥30–<35 and 125 (17.6%) had a BMI ≥35. Most pts were white (92.5–96.8%), middle-aged (mean: 44.5–51.2 yrs) and female (49.5–65.6%). Greater proportions of obese pts were from Russia/Eastern Europe (35.0%) and USA/Canada (31.8%), vs the rest of world. At BL, higher BMI correlated with an increased prevalence of metabolic syndrome (4.3% in BMI <25 to 76.0% in BMI ≥35) and CRP levels >2.87 mg/L (49.1% in BMI <25 to 84.0% in BMI ≥35). Higher proportions of pts (42.5–47.9%) in BL BMI categories <35 reported no prior biologic DMARD use, vs pts with a BL BMI ≥35 (33.6%). At M3, efficacy improvements were greater in tofacitinib-treated pts vs PBO-treated pts (Figure 1). In pts with a BL BMI ≥35, a trend towards fewer pts responding was observed (Figure 1) and mean changes from baseline in SF-36v2 PCS and MCS and FACIT-F generally appeared lower (Figure 2) vs pts in lower BL BMI categories. Up to M3, the proportions of pts with AEs, and percentage change from BL in lipid levels and LFTs, were generally similar across all BL BMI categories. Three CV events were reported: non-fatal cerebrovascular accident, transient ischemic attack (both tofacitinib 5 mg BID, BMI ≥30–<35) and coronary artery revascularisation (PBO; BMI ≥35). Limitations include the 3-month observation time, particularly for safety findings, thus longer observation times are warranted.Conclusion:Regardless of BL BMI, tofacitinib demonstrated greater efficacy than PBO at M3 in pts with PsA. Similar to other advanced therapies,2reduced efficacy was generally observed in tofacitinib and PBO pts with a BL BMI ≥35. Tofacitinib safety appeared consistent across all BL BMI categories.References:[1]Labitigan et al. Arthritis Care Res (Hoboken) 2014;66:600-07.[2]Singh et al. PLoS One 2018;13:e0195123.[3]Mease et al. NEJM 2017;377:1537-50.[4]Gladman et al. NEJM 2017;377:1525-36.Acknowledgments:Medical writing support was provided by Mark Bennett of CMC Connect, McCann Health Medical Communications, and funded by Pfizer Inc.Disclosure of Interests:Christopher T. Ritchlin Grant/research support from: UCB Pharma, AbbVie, Amgen, Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen, Alexis Ogdie Shareholder of: Amgen, Novartis, Pfizer Inc, Grant/research support from: Novartis, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Jon T Giles Grant/research support from: Pfizer Inc, Juan Jesus Gomez-Reino Grant/research support from: AbbVie, Novartis, Pfizer Inc, Roche, UCB, Consultant of: Pfizer Inc, Speakers bureau: AbbVie, Bristol-Myers Squibb, Janssen, MSD, Pfizer Inc, Roche, UCB, Philip Helliwell: None declared, Lori Stockert Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Pamela Young Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Wael Joseph Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Rajiv Mundayat Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Daniela Graham Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, John Woolcott Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Ana Belen Romero Shareholder of: Pfizer Inc, Employee of: Pfizer Inc

The association between body mass index and cardiovascular event in the Korean general population

2016 ◽  
Vol 120 ◽  
pp. S208-S209
Author(s):  
So-Hyeon Hong ◽  
Jee-Young Oh ◽  
Young Sun Hong ◽  
Yeon-Ah Sung ◽  
Kyoung Ae Kong ◽  
...  
Keyword(s):  
Body Mass Index ◽  
General Population ◽  
Body Mass ◽  
Cardiovascular Event

Body mass index and risk of mental disorders in the general population: Results from the Singapore Mental Health Study

2013 ◽  
Vol 74 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Mythily Subramaniam ◽  
Louisa Picco ◽  
Vincent He ◽  
Janhavi Ajit Vaingankar ◽  
Edimansyah Abdin ◽  
...  
Keyword(s):  
Mental Health ◽  
Body Mass Index ◽  
General Population ◽  
Mental Disorders ◽  
Body Mass ◽  
Health Study ◽  
Mental Health Study

scholarly journals Subjective Social Status Is Associated with Dysregulated Eating Behaviors and Greater Body Mass Index in an Urban Predominantly Black and Low-Income Sample

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3893
Author(s):  
Monika M. Stojek ◽  
Paulina Wardawy ◽  
Charles F. Gillespie ◽  
Jennifer S. Stevens ◽  
Abigail Powers ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Social Status ◽  
Body Mass ◽  
Low Income ◽  
Emotional Eating ◽  
Eating Behaviors ◽  
Small Sample Size ◽  
Food Addiction ◽  
Subjective Social Status ◽  
Small Sample

Background: Higher subjective social status (SSS) or a person’s perception of their social standing is related to better health outcomes, but few studies examined SSS in relation to obesity. Emotional eating and food addiction have been linked to obesity. Some studies indicated that manipulating SSS may lead to altered food intake, but the relationship between SSS and dysregulated eating, such as emotional eating and food addiction (FA), has not been examined. The goal of this study was to examine the associations between SSS in the community and the larger society, dysregulated eating (emotional eating and FA), and body mass index (BMI) in a majority racial minority sample. Methods: The participants (N = 89; 93% Black, 86% women, and 56% with obesity; 72% income lower than USD 2000), recruited from a publicly funded hospital in Atlanta, GA, completed the MacArthur Scale, Dutch Eating Behaviors Questionnaire, Yale Food Addiction Scale, Beck Depression Inventory, PTSD Symptom Checklist, and demographics questionnaire. Results: Twenty-two percent of the sample met the criteria for FA; those with FA had significantly higher BMI than those without (p = 0.018). In the hierarchical linear regression, the SSS community (but not in society) predicted higher severity of emotional eating (β = 0.26, p = 0.029) and FA (β = 0.30, p = 0.029), and higher BMI (β = 0.28, p = 0.046), independent from depression and PTSD symptoms. Conclusions: The findings indicate that, among Black individuals with predominantly low income in the U.S., perceived role in their community is associated with eating patterns and body mass. Given the small sample size, the results should be interpreted with caution.

Sign in / Sign up

Export Citation Format

Share Document